Overview
The purpose of this study is to evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324.
Eligibility
Inclusion Criteria:
- Has a body mass index (BMI) of ≥27 kg/m^2 and <40 kg/m^2
Exclusion Criteria:
- Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection
Note: other protocol defined inclusion/exclusion criteria apply